HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Acute rejection of lung transplant — Clinical Guidelines

Overview

Acute rejection of lung transplants is a critical complication that affects over half of transplant recipients despite aggressive immunosuppressive therapy 1. It primarily manifests as an immune response against the transplanted organ, driven predominantly by alloreactive T-lymphocytes, leading to graft dysfunction and potentially chronic rejection 2. This condition significantly impacts patient outcomes, including survival rates and quality of life post-transplantation. Early recognition and management are crucial in day-to-day practice to prevent irreversible damage and improve long-term graft survival 1 2.

Pathophysiology

Acute rejection in lung transplantation involves a complex interplay of cellular and humoral immune responses. The primary mechanism involves recipient T-lymphocytes recognizing donor antigens as foreign, initiating an inflammatory cascade 2. This process is further modulated by genetic factors of the recipient, the type and intensity of immunosuppression, and environmental exposures post-transplant 2. Lymphatic vessels, though controversial, may also play a role in facilitating immune cell trafficking and contributing to the rejection process 1. Additionally, innate immune responses, including toll-like receptor (TLR) polymorphisms, can influence the severity and onset of rejection 20. The activation of monocytes and neutrophils, which generate reactive oxygen intermediates, contributes to tissue injury during rejection 26. Understanding these multifaceted pathways is essential for developing targeted therapeutic strategies.

Epidemiology

Acute cellular rejection affects greater than one-third of lung transplant recipients, with incidence rates varying based on recipient and donor factors 2. Studies suggest no significant differences in rejection rates between donation after brain death (DBD) and donation after circulatory death (DCD) donors, although older donors (>55 years) may have slightly higher risks 6. Geographic variations and specific underlying diseases (e.g., sarcoidosis) can influence rejection rates, with some populations experiencing higher recurrence rates of their primary disease post-transplant 17. Trends over time indicate improvements in immunosuppression protocols but persistent challenges in achieving consistent graft acceptance 1 2.

Clinical Presentation

Acute rejection typically presents with nonspecific symptoms such as dyspnea, cough, fever, and decreased exercise tolerance 1. More severe cases may exhibit hypoxemia, increased airway resistance, and radiographic signs like infiltrates or graft collapse on imaging 3. Red-flag features include rapid clinical deterioration, unexplained decline in lung function tests (e.g., FEV1), and signs of systemic inflammation (elevated CRP). Early detection is critical to prevent progression to chronic rejection and graft failure 1 6.

Diagnosis

The diagnosis of acute rejection after lung transplantation relies heavily on transbronchial biopsy (TBB), which remains the gold standard despite variable diagnostic yields (15%-50% nondiagnostic samples) 5. Biopsy grading systems, such as the International Society for Heart and Lung Transplantation (ISHLT) criteria, are used to assess rejection severity:

Criteria for Diagnosis:

- Transbronchial Biopsy: Essential for definitive diagnosis. - Histologic Grading: - Grade A1: Mild; Grade A2: Moderate; Grade A3: Severe rejection. - Immunosuppressive Monitoring: Levels of tacrolimus, cyclosporine, or other primary immunosuppressants should be within therapeutic ranges. - Laboratory Tests: Elevated inflammatory markers (e.g., CRP, ESR) may support the diagnosis. - Imaging: Chest X-rays or CT scans may show infiltrates or graft collapse, though these are non-specific.

Differential Diagnosis:

- Infection: Bacterial, viral, or fungal; distinguished by cultures and specific serologies. - Acute Respiratory Distress Syndrome (ARDS): Clinical context and biomarkers like surfactant protein D levels. - Drug Toxicity: Evaluate for signs of nephrotoxicity, hepatotoxicity, or neurotoxicity related to immunosuppressive agents. - Chronic Rejection: Histologically distinct, often with bronchiolitis obliterans syndrome (BOS) features 1 5 6.

Management

First-Line Treatment

Steroid Pulse Therapy: Standard initial treatment for acute rejection.

- Drug: Methylprednisolone - Dose: 1-3 g IV over 24 hours - Duration: Single dose or divided over 24 hours - Monitoring: Assess clinical response within 48-72 hours, repeat biopsy if necessary 8 19.

Adjust Immunosuppression:

- Increase Tacrolimus/Cyclosporine: Titrate to maintain therapeutic levels (Trough levels: Tacrolimus 5-15 ng/mL, Cyclosporine 50-200 ng/mL) 18. - Consider Adding Sirolimus: In refractory cases, to enhance immunosuppression 23.

Second-Line Treatment

Alternative Immunosuppressants:

- Mycophenolate Mofetil (MMF): If rejection persists despite steroids and adjusted primary immunosuppression. - Methylprednisolone Maintenance: Continue low-dose steroids if initial pulse therapy is effective but not curative.

Targeted Immunotherapy:

- PD-L1 Gene Therapy: Experimental approach using adeno-associated virus (AAV) vectors to overexpress PD-L1 4. - Interleukin-10 Gene Therapy: Bone marrow stem cells modified with human interleukin-10 (hIL-10) to modulate immune response 11.

Refractory Cases

Consultation with Transplant Immunologist: For complex cases requiring specialized management.

Tacrolimus Rescue Therapy: Conversion from cyclosporine to tacrolimus in cases of refractory rejection 22.

Biologic Agents: Consider monoclonal antibodies targeting specific immune pathways (e.g., anti-CD25, anti-TNFα) under expert guidance.

Complications

Chronic Lung Allograft Dysfunction (CLAD): Persistent decline in lung function, often associated with bronchiolitis obliterans syndrome (BOS).

- Management Trigger: Persistent rejection episodes, declining FEV1, and clinical decline.

Infection: Increased susceptibility due to immunosuppression.

- Management Trigger: Fever, leukocytosis, positive cultures, or clinical deterioration.

Drug Toxicity: Nephrotoxicity, hepatotoxicity, neurotoxicity.

- Monitoring: Regular renal function tests, liver function tests, and neurological assessments.

Graft Loss: Severe or recurrent rejection leading to irreversible graft failure.

- Referral: Immediate referral to transplant specialists for potential re-transplantation or palliative care.

Prognosis & Follow-Up

The prognosis for patients experiencing acute rejection varies based on the severity and timeliness of intervention. Early detection and effective management can mitigate long-term complications, but recurrent rejection episodes are associated with poorer outcomes, including higher rates of chronic rejection and reduced graft survival 10. Recommended follow-up includes:

Regular Biopsies: Every 3-6 months in the first year post-transplant.

Lung Function Tests: Monthly initially, then every 3-6 months.

Immunosuppressive Monitoring: Weekly initially, then monthly.

Clinical Assessments: Regular evaluations for signs of rejection or infection.

Special Populations

Sarcoidosis Patients: Higher risk of recurrent disease post-transplant; close monitoring for both rejection and sarcoid recurrence 17.

Pediatric Recipients: Unique growth and developmental considerations; tailored immunosuppression regimens are crucial [Not explicitly covered in provided sources].

Elderly Recipients: Increased susceptibility to complications; careful titration of immunosuppression to balance rejection risk and toxicity [Not explicitly covered in provided sources].

Key Recommendations

Initiate Steroid Pulse Therapy Promptly for Biopsy-Proven Acute Rejection: (Evidence: Strong 8 19)

Adjust Primary Immunosuppressive Agents to Maintain Therapeutic Levels: (Evidence: Strong 18)

Consider Adding Sirolimus for Refractory Cases: (Evidence: Moderate 23)

Regular Monitoring of Lung Function and Immunosuppressive Drug Levels: Monthly initially, then every 3-6 months (Evidence: Moderate 1 2)

Perform Transbronchial Biopsies Every 3-6 Months in the First Post-Transplant Year: (Evidence: Moderate 5)

Evaluate for and Manage Infection in Patients with Clinical Deterioration: (Evidence: Moderate 1 6)

Consider Targeted Immunotherapies Like PD-L1 Gene Therapy in Experimental Settings: (Evidence: Weak 4)

Refer Complex or Refractory Cases to Transplant Immunologists: (Evidence: Expert opinion)

Monitor for Chronic Lung Allograft Dysfunction (CLAD) Post-Rejection Episodes: (Evidence: Moderate 10)

Implement Weight Management Strategies to Mitigate Rejection Risk: (Evidence: Moderate 9)

References

1 Cui Y, Liu K, Monzon-Medina ME, Padera RF, Wang H, George G et al.. Therapeutic lymphangiogenesis ameliorates established acute lung allograft rejection. The Journal of clinical investigation 2015. link 2 Martinu T, Pavlisko EN, Chen DF, Palmer SM. Acute allograft rejection: cellular and humoral processes. Clinics in chest medicine 2011. link 3 Sohn KH, Park SI, Lee JM, Lee HS, Song MG, Koh YS et al.. Radiologic assessment in pulmonary lobar transplantation. Journal of Korean medical science 1994. link 4 Kahan R, Alderete IS, Gao Q, Hughes B, Zhang M, Gonzalez T et al.. Adeno-associated virus-mediated transduction of PD-L1 in a rodent lung transplant model. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2025. link 5 Kakoullis S, Menachem B, Young K, Mahmood K, Neely M, Ali HA. Inadequate (Ax) Transbronchial Lung Transplant Biopsies-Scope and the Potential Contributing Factors. Transplantation proceedings 2024. link 6 Criner RN, Clausen E, Cantu E. Primary graft dysfunction. Current opinion in organ transplantation 2021. link 7 Tarrant BJ, Robinson R, Le Maitre C, Poulsen M, Corbett M, Snell G et al.. The Utility of the Sit-to-Stand Test for Inpatients in the Acute Hospital Setting After Lung Transplantation. Physical therapy 2020. link 8 Munker D, Arnold P, Veit T, Leuschner G, Ceelen F, Barnikel M et al.. Safety and Efficacy of Steroid Pulse Therapy for Acute Loss of FEV. Transplantation proceedings 2020. link 9 Carvalho Araújo I, Proença Vieira L, di Creddo Alves AC, Naoyuki Samano M, de Oliveira Braga Teixeira RH. Weight Gain and Acute Rejection in Patients Submitted to Pulmonary Transplantation: A Retrospective Cohort of 10 Years. Transplantation proceedings 2018. link 10 Koutsokera A, Levy L, Pal P, Orchanian-Cheff A, Martinu T. Acute Cellular Rejection: Is It Still Relevant?. Seminars in respiratory and critical care medicine 2018. link 11 Pieróg J, Tamo L, Fakin R, Kocher G, Gugger M, Grodzki T et al.. Bone marrow stem cells modified with human interleukin 10 attenuate acute rejection in rat lung allotransplantation. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2018. link 12 Casciello N, Hulbert A, Snyder L, Byrns J. Incidence of acute cellular rejection following granulocyte colony-stimulating factor administration in lung transplantation: A retrospective case-cohort analysis. Clinical transplantation 2017. link 13 Bellon H, Vandermeulen E, Mathyssen C, Sacreas A, Verleden SE, Heigl T et al.. Interleukin-1α induced release of interleukin-8 by human bronchial epithelial cells in vitro: assessing mechanisms and possible treatment options. Transplant international : official journal of the European Society for Organ Transplantation 2017. link 14 Hashimoto K, Besla R, Zamel R, Juvet S, Kim H, Azad S et al.. Circulating Cell Death Biomarkers May Predict Survival in Human Lung Transplantation. American journal of respiratory and critical care medicine 2016. link 15 Westall GP, Paraskeva MA, Snell GI. Antibody-mediated rejection. Current opinion in organ transplantation 2015. link 16 Jamal AJ, Resende MR, Prochnow T, McGilvray I, Pilewski JM, Crespo MM et al.. Simkania negevensis and acute cellular rejection in lung transplant recipients. Clinical transplantation 2015. link 17 Banga A, Sahoo D, Lane CR, Farver CF, Budev MM. Disease Recurrence and Acute Cellular Rejection Episodes During the First Year After Lung Transplantation Among Patients With Sarcoidosis. Transplantation 2015. link 18 Fan Y, Xiao YB, Weng YG. Tacrolimus versus cyclosporine for adult lung transplant recipients: a meta-analysis. Transplantation proceedings 2009. link 19 Fuehner T, Simon A, Dierich M, Dewall C, Laenger F, Pletz MW et al.. Indicators for steroid response in biopsy proven acute graft rejection after lung transplantation. Respiratory medicine 2009. link 20 Palmer SM, Burch LH, Davis RD, Herczyk WF, Howell DN, Reinsmoen NL et al.. The role of innate immunity in acute allograft rejection after lung transplantation. American journal of respiratory and critical care medicine 2003. link 21 Takehisa Y, Sakiyama S, Uyama T, Sumitomo M, Tamaki M, Hino H et al.. Progressive increase of CD4(+)/CD45RC(-) lymphocytes after allograft rat lung transplantation: a marker of acute rejection. The Journal of thoracic and cardiovascular surgery 2002. link 22 Vitulo P, Oggionni T, Cascina A, Arbustini E, D'Armini AM, Rinaldi M et al.. Efficacy of tacrolimus rescue therapy in refractory acute rejection after lung transplantation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2002. link00379-5) 23 Longoria J, Roberts RF, Marboe CC, Stouch BC, Starnes VA, Barr ML. Sirolimus (rapamycin) potentiates cyclosporine in prevention of acute lung rejection. The Journal of thoracic and cardiovascular surgery 1999. link70291-6) 24 Hasegawa T, Iacono A, Yousem SA. The significance of bronchus-associated lymphoid tissue in human lung transplantation: is there an association with acute and chronic rejection?. Transplantation 1999. link 25 Yamamoto H, Okada M, Tobe S, Tsuji F, Ohbo H, Nakamura H et al.. Pulmonary circulatory parameters as indices for the early detection of acute rejection after single lung transplantation. Surgery today 1998. link 26 Shiraishi T, Kuroiwa A, Shirakusa T, Kawahara K, Yoneda S, Kitano K et al.. Free radical-mediated tissue injury in acute lung allograft rejection and the effect of superoxide dismutase. The Annals of thoracic surgery 1997. link00754-6) 27 Kim HK, Severson SR, Ricagna F, Barber DA, Tazelaar HD, Miller VM et al.. Characteristics of endothelin receptors in acutely rejecting transplanted lungs. Transplantation 1997. link 28 Oosterhoff Y, Noordhoek JA, Petersen AH, Kauffman HF, Postma DS, Prop J. There is no activation of O2- production by alveolar macrophages and neutrophil polymorphonuclear leukocytes in rat lung transplants during the reimplantation response and acute rejection. The American review of respiratory disease 1992. link

Acute rejection of lung transplant